tests for two mutations in the GRK3 gene that are
associated with bipolar disorder. Patients who have either of these two
mutations, are Caucasian, of Northern European ancestry and have a family
history of bipolar disorder, are three times more likely to have bipolar
disorder. Psynomics is not currently taking orders for Psynome.
Psynome2™ – tests for mutations in the Promoter L allele gene that predicts patient response to serotonin-based drugs, the most commonly prescribed drug therapies today. No other DNA test exists today to identify an individuals positive or negative response to SSRIs. The serotonin transporter gene is associated with response to SSRI antidepressants, as well as, several other traits including vulnerability to stress induced major depression. Patients with one of two genotype mutations that are Caucasian and suffering from depression, are twice as likely to benefit from treatment with an SSRI type of antidepressant. Psynomics is not currently taking orders for Psynome2.
The identification of each new gene, added to the current list of patented genes, will continue to improve the specificity, sensitivity and diagnostic accuracy and lead to a greater understanding of these diseases. Future genetic discoveries and collaborative relationships will allow Psynomics to expand the range of its tests to include other mental disorders.
Who Will Benefit:
For patients and their families, Psynomics provides up-to-date, informational, diagnostic and treatment resources in complete anonymity.
Because genetics plays a key role in psychiatric disorders, Psynomics’ diagnostics help the immediate families of the afflicted populations in assessing their own exposure.
For mental health professionals, Psynomics will enable physicians to provide state-of-the-art, DNA-based evaluation to aid in diagnosis and selecting optimal treatment for patients.
Initially, Psynomics will limit its testing to those patients already exhibiting symptoms to help confirm the genetic cause and the risk of developing bipolar disorder. The company will not test individuals who have no symptoms but want to know their likelihood of developing bipolar disorder.
Benefits for Patients:
Benefits for Physicians: